First patients treated with Elekta VMAT – a major advance in radiation therapy treatments

Crawley, UK, February 04, 2008

Patients at the Royal Marsden Hospital in Sutton UK and Allgemeines KrankenHaus / Medical University of Vienna in Austria have successfully completed the world’s first image guided intensity modulated arc therapy treatments using commercially released product solutions.

The Royal Marsden Hospital pioneered clinical use of an Elekta Synergy® image guided system fitted with the new Elekta linear accelerator control system in order to deliver volumetric intensity modulated arc therapy (VMAT) to a patient undergoing a course of radiation therapy treatment for lung cancer.

“On Monday 28th of January we treated our first patient with the VMAT (Volumetric intensity Modulated Arc Therapy) technique” reports Jim Warrington, Head of Radiotherapy Physics at the Royal Marsden. “The patient received a single 340˚ arc of 6MV x-rays, with simultaneously variable gantry rotation speed, dose rate and dynamic multi-leaf collimator modulation. The treatment arc delivered a 2 Gray fraction to the target in 93 seconds.” He continued “the efficiency and flexibility of this technique is impressive and we hope to be able to expand the use of this advanced new treatment method to become routine practice in the future. We anticipate that when used in conjunction with our Elekta Synergy image guidance systems and employing non-coplanar angles of delivery, VMAT will be a significantly improved treatment modality for the Royal Marsden’s radiotherapy patients” he concludes.

The two main benefits of this unique Elekta technology promise to be significant reduction in treatment time (in the case of the Royal Marsden treatment, 50% from the patient’s previous conformal plan) combined with a significant improvement in conformance to the target and sparing of dose to adjacent healthy tissues. An additional benefit of reducing treatment times is greater comfort for the patient which in turn, by making it easier for the patient to keep still, increases the likelihood of delivering radiation beams more accurately as targeted.

During the same week, Allgemeines KrankenHaus / Medical University of Vienna (AKH) in Austria delivered the world’s first PreciseBEAM VMAT treatment. PreciseBEAM VMAT is delivered as a combination of optimized treatment planning using Ergo++ and an Elekta Synergy linear accelerator, upgraded with a next generation digital control system.

The treatment was to an intracranial glioblastoma and consisted of 3 non-coplanar VMAT arcs with variable gantry speed and simultaneous leaf movement and rotation of the dynamic multileaf collimator. The Elekta Accelerators are unique in their ability to deliver this level of movement complexity. The patient had an important brain lesion very close to important vital structure such as hypophisys, brain stem, optical nerves, and lenses of the eyes, however the treatment was completed within 10 minutes – including set-up, imaging, repositioning and delivery.

“The new system will revolutionize the practice of tailored intensity modulated radiotherapy during the next decade”, commented, Prof. Dr. Richard Pötter. the Chief Medical Doctor at AKH “Very soon not only head and neck lesions but also tumors in the lung, close to the cervical spine and in the pelvis will be treated with VMAT.”

“For many years AKH has been practicing a technique called IMRT. The new technique VMAT adds the possibility of modulating the radiation intensity during an arc treatment. The advantage is an even better sparring of healthy organs and a more effective and better targeted irradiation of the tumor … At the same time the total treatment time is significantly reduced from 15 minutes to 6 – 7 minutes which is of highest importance for patients with serious diseases” continues Prof. Dr. Pötter.

Referring to their first patient treatment, Prof. Dr. Dietmar Georg, Chief Medical Physicist continues, “This therapy will currently be applied in very complex situations where the localisation and the form of the tumor requires tailored intensity modulated treatment. Not every patient will be an appropriate candidate for this novel therapy, but we will work hard to investigate how we can make more use of this new treatment technique.”

The University Clinic for Radiotherapy at AKH is honored to have been selected by Elekta, the manufacturer, to employ this new treatment technique. “In this way we are at the forefront of the leading radiation oncology hospitals in the world who collaborate on the introduction of new therapies, VMAT will give us an enormous impetus both scientifically as well as in medical care”. agreed Prof. Georg and Prof. Dieckmann

“On top of improving the utilization of existing radiotherapy equipment (these innovations are available as upgrade packages for existing Elekta accelerators) with the potential to reduce waiting lists for treatment,” explains Olof Sanden, Elekta Executive Vice President Europe, “the improved conformance gives physicians the opportunity to either reduce the likelihood of unwanted side-effects at previously prescribed doses or increase the dose to the tumor whilst maintaining existing side-effect profiles – which in turn could lead to improved treatment outcomes.”

“Almost ten years of research in collaboration with members of the Elekta IMRT Consortium has lead to this unique series of innovations” explains Dee Mathieson, Elekta Business Area Manager, Oncology. “We started by setting ourselves the objective of removing the technical limitations presented by existing technology to give physicians ultimate flexibility in the planning of radiation therapy treatments. The real challenge was to achieve this level of freedom using existing treatment machines already installed in hospitals today. Having already developed the worlds only fully digital accelerator proved to be a key element in making this level of automation and control complexity possible in a way that allows clinicians to deliver advanced treatments with a single push of a button. Development of this unique technology has also delivered integration, automation and control benefits to our equipment’s ability to deliver a whole portfolio of dynamic intensity modulated and conventional conformal therapies, and we are looking forward to implementing these patented developments across all of our oncology products” she concludes.

Olof summarizes, “ we are I think justifiably proud to have introduced both the world’s first linear accelerator with integrated 3D imaging at the time of treatment and to be able to fully exploit the benefits that technology offers through introducing the world’s first accelerator capable of delivering VMAT”. Of course the really exciting thing as this technology rolls out into more and more hospitals will be to discover the true benefits it will enable our customers to deliver to their patients. We are especially grateful to our development partners pioneering the application of these technologies which allows us to develop training programs and protocols to support introduction to the wider radiotherapy community.”

[VMAT capability is CE marked as part of the new linear accelerator control system and may require additional regulatory clearances for sale in other regions of the world. Potential customers should contact their local Elekta office for further details.]

For further information, please contact:

Investor Enquiries:

Peter Ejemyr, Group VP Corporate Communications.
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com

Global Marketing Enquires:

Peter J. Gaccione, Vice President, Global Marketing
Tel: +1 770 670 2380, email: peter.gaccione@elekta.com

Product Enquiries Europe, Asia & South America:

David Gosnell, Oncology Product Launch Manager
Tel: +44 (0) 1293 654729, e-mail: david.gosnell@elekta.com

Media Enquiries North America:

Michelle Lee, PR and Advertising Manager
Tel: +1 770-670-2447, email: michelle.lee@elekta.com

Media Enquiries Europe, Asia & South America:

Joanne Latimer, Healthcare Communications Specialist
Tel: +44 (0) 1293 654729 , e-mail: joanne.latimer@elekta.com

About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta’s solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT ). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world’s largest supplier of oncology software.

Elekta’s systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 2,000 employees, Elekta’s corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please click here .